Chao Ce, Mei Kun, Wang Min, Tang Renzhe, Qian Yongxiang, Wang Bin, Di Dongmei
Department of Cardiothoracic Surgery, The Third Affiliated Hospital of Soochow University, Changzhou, 213003, China.
Heliyon. 2023 Jul 22;9(8):e18502. doi: 10.1016/j.heliyon.2023.e18502. eCollection 2023 Aug.
The lymph node ratio (LNR) is useful for predicting survival in patients with small cell lung cancer (SCLC). The present study compared the effectiveness of the N stage, number of positive LNs (NPLNs), LNR, and log odds of positive LNs (LODDS) to predict cancer-specific survival (CSS) in patients with SCLC.
674 patients were screened using the Surveillance Epidemiology and End Results database. The Kaplan-Meier survival and receiver operating characteristic (ROC) curves were performed to address optimal estimation of the N stage, NPLNs, LNR, and LODDS to predict CSS. The optimal LN status group was incorporated into a nomogram to estimate CSS in SCLC patients. The ROC curve, decision curve analysis, and calibration plots were utilized to test the discriminatory ability and accuracy of this nomogram.
The LODDS model showed the highest accuracy compared to the N stage, NPLNs, and LNR in predicting CSS for SCLC patients. LODDS, age, sex, tumor size, and radiotherapy status were included in the nomogram. The results of calibration plots provided evidences of nice consistency. The ROC and DCA plots suggested a better discriminatory ability and clinical applicability of this nomogram than the 8th TNM and SEER staging systems.
LODDS demonstrated a better predictive power than other LN schemes in SCLC patients after surgery. A novel LODDS-incorporating nomogram was built to predict CSS in SCLC patients after surgery, proving to be more precise than the 8th TNM and SEER staging.
淋巴结比率(LNR)有助于预测小细胞肺癌(SCLC)患者的生存率。本研究比较了N分期、阳性淋巴结数量(NPLNs)、LNR和阳性淋巴结对数优势比(LODDS)预测SCLC患者癌症特异性生存(CSS)的有效性。
使用监测、流行病学和最终结果数据库筛选出674例患者。采用Kaplan-Meier生存曲线和受试者工作特征(ROC)曲线来确定N分期、NPLNs、LNR和LODDS预测CSS的最佳估计值。将最佳淋巴结状态组纳入列线图以估计SCLC患者的CSS。利用ROC曲线、决策曲线分析和校准图来测试该列线图的辨别能力和准确性。
在预测SCLC患者的CSS方面,与N分期、NPLNs和LNR相比,LODDS模型显示出最高的准确性。列线图纳入了LODDS、年龄、性别、肿瘤大小和放疗状态。校准图结果提供了良好一致性的证据。ROC和DCA图表明,该列线图比第八版TNM和SEER分期系统具有更好的辨别能力和临床适用性。
在接受手术的SCLC患者中,LODDS显示出比其他淋巴结方案更好的预测能力。构建了一个纳入LODDS的新型列线图来预测SCLC患者术后的CSS,结果证明该列线图比第八版TNM和SEER分期更精确。